Hospital Israelita Albert Einstein (Eretz.bio)

Eretz.bio is the incubator and investment program of Hospital Israelita Albert Einstein, widely regarded as Latin America’s top hospital, headquartered in Sao Paulo. The vehicle invests at pre-seed and seed stages with check sizes that vary based on strategic priority, and its focus spans AI/ML in healthcare, biotech, medical devices, and digital health. Because Eretz.bio is the corporate venture and innovation arm of one of the most respected academic medical centers in the region, the strategic value of investment is substantial: portfolio companies can pilot products inside Einstein’s clinical environment, access research collaborations with Einstein’s medical staff, and benefit from the hospital’s brand credibility when selling to other Latin American providers and international partners. The geographic focus is Brazil with selective international engagement through Einstein’s global research and clinical networks. The right founder profile is a digital health, biotech, AI-for-healthcare, or medical device founder whose product genuinely benefits from deep clinical integration with a top-tier academic medical center, ideally with a working product or strong scientific validation that can be tested in Einstein’s environment. The wrong fit is a consumer health brand with no clinical integration angle, or a US-first SaaS company that treats Brazil as an afterthought. The right entry path is through Einstein’s innovation team and Eretz.bio’s structured incubation program, through warm introductions from existing portfolio companies, through Sao Paulo healthtech operator networks, and through alumni of Einstein’s clinical and research ecosystem. When pitching, lead with the strategic fit to Einstein’s clinical, research, or operational priorities and quantify the operating value of integration, then connect to the standalone commercial trajectory beyond Einstein. Avoid pitching as a generic Brazilian seed check; the strategic and clinical logic is the entire point. Caveats: founders should think carefully about strategic conflicts and exclusivity, particularly if the company hopes to sell to competing Brazilian or international hospital networks, and should structure terms with normal venture optionality. The check size and stage focus also mean Eretz.bio is best understood as a foundational early partner rather than a Series A lead. Use Eretz.bio when the clinical and research partnership with Einstein is genuinely transformative for the business, not as a generic Brazilian healthtech check.